Company intelligence / Profile preview

HRA Pharma Rare Diseases

Châtillon, France

Ownership: Private
Employees: ~100
Development stage: Other

Overview

HRA Pharma Rare Diseases is a specialized pharmaceutical company dedicated to improving the lives of patients with rare diseases, primarily in the field of endocrinology. The company focuses on the development and commercialization of orphan drugs for conditions with high unmet medical needs, such as Cushing's syndrome and Adrenocortical Carcinoma. Its commercial portfolio includes established therapies like Metopirone, Lysodren, and Ketoconazole HRA. Originally a business unit of HRA Pharma, the entity was acquired by Perrigo in 2022 and continues to operate as a leader in niche endocrine oncology and rare metabolic disorders.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on HRA Pharma Rare Diseases.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRA Pharma Rare Diseases.

Explore the full profile